ERBB2 and cancer: Another mechanism as to how EV can impede cancer therapy is that cancer cells have been shown to export therapeutic targets such as CD20, Her2/Neu, or PD-L1 onto Exo [142,143,144] that capture the administered therapeutic antibodies and shield the tumor cells from attack, resulting in therapy failure.